recombinant human Angiostatin protein + paclitaxel + carboplatin
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
— → Dec 1, 2004
NCT ID
NCT00049790About recombinant human Angiostatin protein + paclitaxel + carboplatin
recombinant human Angiostatin protein + paclitaxel + carboplatin is a phase 2 stage product being developed by CASI Pharmaceuticals for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00049790. Target conditions include Carcinoma, Non-Small-Cell Lung.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00049790 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung